Larotrectinib market price overview in 2024

Larotinib, a cutting-edge targeted anti-cancer drug, has attracted widespread attention since its launch. However, its high price has always been a major problem for patients in the medication process. Entering 2024, the selling price of larotrectinib in the Chinese market remains high, with the price of a single box of the drug often reaching tens of thousands of yuan, which undoubtedly poses heavy financial pressure to many patients.

Since larotrectinib has not yet been included in China's medical insurance catalog, patients need to bear all the drug costs themselves. This is undoubtedly unaffordable for patients with limited financial conditions. Not only do they have to deal with the pain of the disease, but they also have to worry about the high cost of medicines.

However, overseas markets provide patients with new options. In Laos, generic larotrectinib produced by Lucius Pharmaceuticals and ASEAN Pharmaceuticals has attracted much attention. The 100mg*30 capsule version of Lucius Pharmaceuticals is relatively affordable at just over a thousand RMB. ASEAN Pharmaceuticals offers a variety of specifications such as 25mg*60 capsules and 100mg*60 capsules, priced at around one thousand and five thousand RMB respectively, meeting the needs of different patients.

In addition, generic drugs of larotrectinib produced by Ziska Pharmaceuticals and Yipin International have also emerged in the Bangladeshi market. Ziska Pharmaceutical's 100mg*30 tablets version is priced at about 3,000 yuan; while Yaopin International's drug of the same specification is priced slightly higher, at about more than 4,000 yuan. The launch of these generic drugs not only enriches patients' choices, but also reduces their economic burden to a certain extent.

In general, although the market price of larotrectinib will still be high in 2024, the rise of overseas generic drugs has brought new hope to patients. In the future, with the launch of more generic drugs and the continuous improvement of medical insurance policies, it is believed that more patients will be able to afford this advanced targeted anti-cancer drug.